Impel Pharmaceuticals Inc. Common Stock
IMPL
IMPL was delisted on the 15th of December, 2023.
45 hedge funds and large institutions have $132M invested in Impel Pharmaceuticals Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 4 reducing their positions, and 11 closing their positions.
325% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 4
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
2% more funds holding
Funds holding: 44 → 45 (+1)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
41% less capital invested
Capital invested by funds: $222M → $132M (-$90.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.08M |
| 2 |
Two Sigma Investments
New York
|
+$1.42M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.27M |
| 4 |
DA
DCF Advisers
Greenwich,
Connecticut
|
+$1.06M |
| 5 |
BlackRock
New York
|
+$862K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$3.78M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$2.44M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.69M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.22M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$979K |
IMPL Hedge Fund Activity: Q4 2021 in Review
45 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q4 2021, worth a combined $132M — down 41% from $222M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IMPL positions and 11 closed out — a net gain of 3 holders — while 17 added to existing stakes and 4 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.08M. The largest seller was Ardsley Advisory Partners, exiting entirely with an estimated $3.78M sold.
- 45 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q4 2021, up from 44 in Q3 2021.
- Funds reported $132M of Impel Pharmaceuticals Inc. Common Stock stock for Q4 2021, down 41% quarter-over-quarter.
- 14 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q4 2021 and 11 closed out, a net change of +3 holders.
- The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q4 2021 was Point72 Asset Management, an estimated $2.08M added.
- The largest Impel Pharmaceuticals Inc. Common Stock seller in Q4 2021 was Ardsley Advisory Partners, an estimated $3.78M sold.
Based on aggregated 13F filings for Q4 2021.